Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 2Hemangiosarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Endometrial Stromal 1Pathologic Complete Response 1Oligodendroglioma 1Neoplasms 1Gliosarcoma 1Glioblastoma 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Endometrial Stromal × trebananib × Sarcoma × Clear all
NCT01210222 2018-02-23

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

GOG Foundation

Phase 2 Completed
35 enrolled 9 charts
GynecologicSarcoma

Sarcoma, Endometrial Stromal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡